 |
인쇄하기
취소
|
Pfizer to launch an oral quit-smoking drug, Champix next year.
A phase III clinical study for a new conceptional oral quit-smoking drug called Champix (Varenicline) reported its efficacy for all Asians including Korean smokers.
The phase III study involved about 250 smokers in Taiwan and Korea reported 59.3% of 12 week's stop smoking success (compared to 32.3% of placebo groups) after 24 weeks including 12 weeks treatment and other 12 weeks of free med...
The phase III study involved about 250 smokers in Taiwan and Korea reported 59.3% of 12 week's stop smoking success (compared to 32.3% of placebo groups) after 24 weeks including 12 weeks treatment and other 12 weeks of free med...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.